Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

@article{Rothman2001AmphetaminetypeCN,
  title={Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin},
  author={R. Rothman and M. Baumann and C. Dersch and D. V. Romero and K. Rice and F. Carroll and J. Partilla},
  journal={Synapse},
  year={2001},
  volume={39}
}
A large body of evidence supports the hypothesis that mesolimbic dopamine (DA) mediates, in animal models, the reinforcing effects of central nervous system stimulants such as cocaine and amphetamine. The role DA plays in mediating amphetamine‐type subjective effects of stimulants in humans remains to be established. Both amphetamine and cocaine increase norepinephrine (NE) via stimulation of release and inhibition of reuptake, respectively. If increases in NE mediate amphetamine‐type… Expand
View on Wiley
lycaeum.org
853 Citations
Highly Influential Citations
59
Background Citations
387
Methods Citations
46
Results Citations
28

853 Citations

Citation Type

Citation Type

Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey
TLDR
It is demonstrated that increasing serotonergic activity attenuates dopamine release and dopamine-mediated behavioral effects of monoamine releasers and supports further investigation of PAL-313 and similar compounds as a potential medication for treating psychostimulant abuse. Expand
The Effects of Amphetamine and Methamphetamine on the Release of Norepinephrine, Dopamine and Acetylcholine From the Brainstem Reticular Formation
TLDR
The mechanistic approach followed here to describe the action of AMPHs within the RF is rooted on the fine anatomy of this region of the brainstem, and a number of reticular nuclei beyond classic DA mesencephalic cells are considered to extend the scenario underlying the neurobiology of AM PHs abuse. Expand
Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.
TLDR
Comparing effects of four novel DA/5HT releasers that varied >800-fold in their selectivities suggests that potency to release NE has minimal influence on abuse liability of dualDA/5 HT releasers, and reducing relative potency torelease NE versus DA/ 5HT does not improve anticocaine efficacy. Expand
Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats
TLDR
The selective effectiveness of amphetamine maintenance to treat cocaine abuse may reflect attenuation of cocaine- induced increases in NAc DA while preserving cocaine-induced increases inNAc 5-HT. Expand
Noradrenergic and dopaminergic effects of (+)‐amphetamine‐like stimulants in the baboon Papio anubis
TLDR
The present data indicate that typical clinical doses of phentermine and (±)‐ephedrine may not release central DA in humans, a hypothesis that should ultimately be tested in controlled clinical studies. Expand
Dopamine/serotonin releasers as medications for stimulant addictions.
TLDR
It is concluded that DA/5-HT releasers could be useful therapeutic adjuncts for the treatment of cocaine and alcohol addictions as well as for obesity, attention deficit disorder and depression. Expand
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.
TLDR
It is concluded that DA/5-HT releasers could be useful therapeutic adjuncts for the treatment of cocaine and alcohol addictions, as well as for obesity, attention-deficit disorder, and depression. Expand
Effects of “Legal X” Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain
TLDR
The hypothesis that the BZP/TFMPP combination mimics the neurochemical mechanism of MDMA, providing a basis for recreational use of these agents, is supported and the findings suggest possible drug‐drug synergism when piperazine drugs are coadministered at high doses. Expand
Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration
TLDR
The findings reported here demonstrate that nonamphetamine monoamine releasing agents such as PAL-287 might be promising candidate medications for the treatment of stimulant dependence. Expand
Pharmacology, neurobiology and neurotoxicity of methamphetamine
TLDR
Evidence of MA’s neurotoxic effects is presented to develop research strategies towards prospective designs looking at large cohorts of young people belonging to a risk group for recreational drug use. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Neurochemical neutralization of methamphetamine with high‐affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse
TLDR
An in vitro assay is established which selectively detects transporter substrates and used to profile the ability of a lead compound, indatraline, to block the releasing effects of METH and MDMA at the DA, 5‐HT, and NE transporters. Expand
Biological and behavioral responses to d-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers
TLDR
Results suggest that some but not most of D-amphetamine's biological and behavioral effects may be modified by a 5-HT3 antagonist in healthy human volunteers. Expand
Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data
TLDR
Data regarding the effects of dopamine agonists and antagonists on the discriminative stimulus effects of amphetamine in animals and its subjective effects in humans are reviewed. Expand
Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers
TLDR
Pimozide did not produce any effects when administered alone and produced inconsistent effects on responses to d-amphetamine, raising the possibility that the role of dopamine in the subjective effects of stimulants may be more complex than initially appreciated. Expand
High Dose Pimozide Does Not Block Amphetamine-Induced Euphoria in Normal Volunteers
  • L. Brauer, H. Wit
  • Medicine, Psychology
  • Pharmacology Biochemistry and Behavior
  • 1997
TLDR
Pimozide failed to consistently antagonize the effects of d-amphetamine, even at doses of pimozide that had behavioral and physiological effects when administered alone, as well as on psychomotor performance and physiological measures. Expand
The interaction of cocaine with serotonin dorsal raphe neurons. Single-unit extracellular recording studies.
  • K. Cunningham, J. Lakoski
  • Chemistry, Medicine
  • Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • 1990
TLDR
The hypothesis that the inhibitory effects of cocaine on 5- HT DRN neurons are mediated by increased 5-HT available for interaction with5-HT1A impulse-regulating autoreceptors in the DRN is supported, as a consequence of cocaine-induced blockade of 5-ht reuptake processes. Expand
Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man
TLDR
This study suggests that it is unlikely that these central actions in man are a consequence of the release of norepinephrine in the brain, and suggests that these five agents share a common mode of central action. Expand
Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans
TLDR
Data indicate that withdrawal from chronic cocaine renders specific subpopulations of postsynaptic 5-HT1A receptors subsensitive and 5- HT2A/2C receptors supersensitive and it is proposed that withdrawalFrom chronic cocaine in rats may serve as a useful animal model of depressive disorders. Expand
Doses of GBR12909 that suppress cocaine self‐administration in non‐human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans
TLDR
These data strongly suggest that occupancy for the DA transporter by GBR explains its ability to attenuate cocaine‐induced increases in extracellular DA and to suppress cocaine self‐administration and suggest that experimental human studies of orally administered GBR to test the DA hypothesis of cocaine addiction should use doses that produce at least 70% occupancy of theDA transporter. Expand
Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction.
TLDR
The finding that PHEN-induced place preferences were attenuated by doses of FEN demonstrates that the combination of F EN/PHEN is devoid of motivational effects, and provides a strong rationale for pursuing controlled clinical trials in humans with agents that act via a similar mechanism of action. Expand
...
1
2
3
4
5
...